These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 15927364

  • 1. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.
    Slack A, Lozano G, Shohet JM.
    Cancer Lett; 2005 Oct 18; 228(1-2):21-7. PubMed ID: 15927364
    [Abstract] [Full Text] [Related]

  • 2. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
    Slack AD, Chen Z, Ludwig AD, Hicks J, Shohet JM.
    Cancer Res; 2007 Mar 15; 67(6):2448-55. PubMed ID: 17363562
    [Abstract] [Full Text] [Related]

  • 3. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
    Chen Z, Lin Y, Barbieri E, Burlingame S, Hicks J, Ludwig A, Shohet JM.
    Neoplasia; 2009 Aug 15; 11(8):753-62. PubMed ID: 19649205
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. MDM2 as a critical effector of the MYCN oncogene in tumorigenesis.
    Slack A, Shohet JM.
    Cell Cycle; 2005 Jul 15; 4(7):857-60. PubMed ID: 15917661
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.
    Carr-Wilkinson J, Griffiths R, Elston R, Gamble LD, Goranov B, Redfern CP, Lunec J, Tweddle DA.
    Cell Cycle; 2011 Nov 01; 10(21):3778-87. PubMed ID: 22052359
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
    Buechner J, Henriksen JR, Haug BH, Tømte E, Flaegstad T, Einvik C.
    Differentiation; 2011 Jan 01; 81(1):25-34. PubMed ID: 20980091
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
    Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, Chung DH.
    Biochem Biophys Res Commun; 2006 Dec 08; 351(1):192-7. PubMed ID: 17055458
    [Abstract] [Full Text] [Related]

  • 16. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
    Shohet JM, Ghosh R, Coarfa C, Ludwig A, Benham AL, Chen Z, Patterson DM, Barbieri E, Mestdagh P, Sikorski DN, Milosavljevic A, Kim ES, Gunaratne PH.
    Cancer Res; 2011 Jun 01; 71(11):3841-51. PubMed ID: 21498633
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma.
    Selmi A, de Saint-Jean M, Jallas AC, Garin E, Hogarty MD, Bénard J, Puisieux A, Marabelle A, Valsesia-Wittmann S.
    Cancer Lett; 2015 Feb 01; 357(1):412-418. PubMed ID: 25475555
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma.
    Gupta A, Williams BR, Hanash SM, Rawwas J.
    Cancer Res; 2006 Aug 15; 66(16):8100-8. PubMed ID: 16912187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.